BSX:NYSE
Boston Scientific Corp
$43.88
arrow_downward
-0.52%(-0.23) 1D
$43.63
arrow_downward
-0.56% (-0.25)bedtimeAfter hours
Closed: Sep 29, 4:00:04 PM GMT-4 · USD
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BSX...
Open
$44.14
High
$44.30
Low
$43.22
Mkt. cap
63.59B
Avg. vol.
21.27M
Volume
14.60M
P/E ratio
17.79
52-wk high
$105.65
52-wk low
$42.20
EPS
$2.47
Beta
0.57
Shares outstanding
1.45B
No. of employees
59K
Open
$44.14
High
$44.30
Low
$43.22
Mkt. cap
63.59B
Avg. vol.
21.27M
Volume
14.60M
P/E ratio
17.79
52-wk high
$105.65
52-wk low
$42.20
EPS
$2.47
Beta
0.57
Shares outstanding
1.45B
No. of employees
59K
News stories
From web sources and news partners
Pluang
·
13 hours ago
Boston Scientific shares fall 55% amid challenges but underlying business shows growth potential
Seeking Alpha
·
14 hours ago
Boston Scientific: Market Pessimism Has Pushed The Stock Into Undervalued Territory (NYSE:BSX)
Yahoo Finance
·
1 day ago
How Big Could BSX Stock's Next Fall Be?
Trefis
·
1 day ago
How Big Could BSX Stock’s Next Fall Be?
Profile
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
About Boston Scientific Corp
CEOMichael F. Mahoney
Employees59K
FoundedJun 29, 1979
HeadquartersMarlborough, Massachusetts, United States
SectorMedical device
Websitebostonscientific.com
Analyst ratings
Based on 21 analysts giving stock ratings to BSX in the past 3 months
Strong buy
Buy
18
Hold
3
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for BSX in the last 3 months.
Highest
Current $43.88
$70.00 (+59.53%)
Average
$58.58 (+33.50%)
Lowest
$48.00 (+9.39%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Larry Biegelsen Wells Fargo | Hold | Reiterated | $48.00 | +9.4% | 09/24/2026 |
Suraj Kalia Oppenheimer | Buy | Reiterated | $65.00 | +48.1% | 09/21/2026 |
Travis Steed Bank of America Securities | Buy | Maintained | $54.00 | +23.1% | 09/20/2026 |
Josh Jennings TD Cowen | Buy | Maintained | $56.00 | +27.6% | 09/17/2026 |
Joanne Wuensch Citi | Hold | Downgraded | $50.00 | +13.9% | 09/18/2026 |
Matthew Taylor Jefferies | Buy | Maintained | $60.00 | +36.7% | 09/11/2026 |
Richard Newitter Truist Financial | Buy | Maintained | - | - | 09/09/2026 |
Marie Thibault BTIG | Buy | Reiterated | $56.00 | +27.6% | 09/09/2026 |
David Toung Argus Research | Hold | Downgraded | - | - | 07/30/2026 |
Anthony Petrone Mizuho Securities | Buy | Maintained | $60.00 | +36.7% | 07/31/2026 |
Robbie Marcus J.P. Morgan | Buy | Reiterated | $56.00 | +27.6% | 07/30/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $55.00 | +25.3% | 07/30/2026 |
Pito Chickering Deutsche Bank | Buy | Maintained | $60.00 | +36.7% | 07/30/2026 |
David Rescott Robert W. Baird | Buy | Maintained | $56.00 | +27.6% | 07/30/2026 |
William Plovanic Canaccord Genuity | Buy | Reiterated | $66.00 | +50.4% | 07/30/2026 |
Kendall Au RBC Capital | Buy | Reiterated | $70.00 | +59.5% | 07/29/2026 |
Shagun Singh Chadha RBC Capital | Buy | Reiterated | $70.00 | +59.5% | 07/29/2026 |
Mike Kratky Leerink Partners | Buy | Maintained | $60.00 | +36.7% | 07/30/2026 |
Michael Matson Needham | Buy | Maintained | $57.00 | +29.9% | 07/29/2026 |
Patrick Wood UBS | Buy | Maintained | $67.00 | +52.7% | 07/30/2026 |
Rick Wise Stifel Nicolaus | Buy | Maintained | $60.00 | +36.7% | 07/29/2026 |
Unknown Analyst Oppenheimer | Buy | Maintained | $85.00 | +93.7% | 07/27/2026 |
David Roman Goldman Sachs | Buy | Maintained | $57.00 | +29.9% | 07/14/2026 |
Matthew O'Brien Piper Sandler | Buy | Maintained | $65.00 | +48.1% | 06/12/2026 |
Stephanie Elghazi Bank of America Securities | Buy | Maintained | $68.00 | +55% | 06/09/2026 |
Michael Polark Wolfe Research | Hold | Downgraded | - | - | 05/29/2026 |
Matt Miksic Barclays | Buy | Maintained | $89.00 | +102.8% | 05/28/2026 |
Christopher Pasquale Nephron | Buy | Upgraded | $85.00 | +93.7% | 04/23/2026 |
Hans Engel Erste Group | Hold | Reiterated | - | - | 04/01/2026 |
Jayson Bedford Raymond James | Buy | Maintained | $88.00 | +100.5% | 03/27/2026 |
Danielle Antalffy UBS | Buy | Reiterated | $105.00 | +139.3% | 03/17/2026 |
Lee Hambright Bernstein | Buy | Maintained | $112.00 | +155.2% | 02/05/2026 |
Last report
Jul 29, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.86 / $0.83
+3.86%beat
arrow_upward
Revenue / Est. (USD)
5.44B / 5.37B
+1.42%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 5.06B | 5.29B | 5.20B | 5.44B |
Cost of goods sold | 1.54B | 1.61B | 1.60B | 1.61B |
Cost of revenue | 1.54B | 1.61B | 1.60B | 1.61B |
Research and development expenses | 514.00M | 569.00M | 516.00M | 554.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.74B | 1.83B | 1.78B | 1.80B |
Operating expense | 2.48B | 2.63B | 2.53B | 2.59B |
Total operating expenses | 4.02B | 4.24B | 4.13B | 4.20B |
Operating income | 1.05B | 1.04B | 1.07B | 1.25B |
Other non operating income | -16.00M | 28.00M | 28.00M | -6.00M |
EBT including unusual items | 938.00M | 700.00M | 1.16B | 1.06B |
EBT excluding unusual items | 935.00M | 1.01B | 999.00M | 1.14B |
Income tax expense | 183.00M | 30.00M | -176.00M | 155.00M |
Effective tax rate | 19.51% | 4.29% | -15.13% | 14.62% |
Other operating expenses | - | - | - | - |
Net income | 755.00M | 672.00M | 1.34B | 907.00M |
Net profit margin | 14.91% | 12.71% | 25.77% | 16.67% |
Earnings per share | 0.75 | 0.80 | 0.80 | 0.86 |
Interest and investment income | - | 29.00M | - | 11.00M |
Interest expense | -87.00M | -90.00M | -90.00M | -96.00M |
Net interest expenses | -87.00M | -61.00M | -90.00M | -85.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.39B | 1.41B | 1.42B | 1.60B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1